Influenza is a contagious respiratory infection that can range from mild illness to severe complications and hospitalization. Seasonal outbreaks continue to place pressure on healthcare systems, particularly among elderly populations, children, and people with underlying conditions. Growing awareness of preventive healthcare and the need to reduce influenza-related complications are supporting demand for effective immunization programs worldwide.

The Influenza Vaccines Market was valued at approximately US$7.48 billion in 2021 and is projected to reach US$12.27 billion by 2028, expanding at a CAGR of 7.4% from 2022 to 2028. Increasing vaccination coverage, product innovation, government immunization initiatives, and investments in vaccine manufacturing are among the major factors supporting this growth. The industry is segmented by vaccine type, virus type, technology, route of administration, target group, and geography.

Get Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00004070

Rising Influenza Burden and Growing Vaccination Demand

The continued prevalence of seasonal influenza is a key factor driving vaccine adoption. According to the World Health Organization, seasonal influenza can result in millions of severe cases and hundreds of thousands of respiratory deaths globally each year. Such disease burden encourages governments and healthcare organizations to strengthen annual vaccination programs.

The COVID-19 pandemic further highlighted the importance of respiratory disease prevention and increased public awareness regarding vaccination. In the US, influenza vaccine administration increased during the 2020 vaccination season compared with previous years, reflecting greater attention to respiratory infections and preventive healthcare. Increasing vaccination among adults, elderly individuals, and high-risk populations is expected to create sustained demand.

Quadrivalent Vaccines Lead Product Adoption

Based on vaccine type, the global industry is segmented into quadrivalent and trivalent vaccines. Quadrivalent vaccines accounted for the largest share, representing 88.1% in 2021. Their ability to provide protection against four influenza virus strains has supported their adoption across national immunization programs and healthcare settings.

The segment is also expected to maintain strong growth through 2028, supported by product approvals, launches, and increasing preference for broader strain coverage. Manufacturers are focusing on developing vaccines that can improve protection and address changing influenza virus patterns.

By virus type, influenza virus type A held a leading position in 2021 and is expected to register a CAGR of 7.6% during the forecast period. Type A is widely recognized as an important cause of seasonal influenza and has the potential to infect both humans and animals, contributing to continued surveillance and vaccine development efforts.

Technological Advancements Strengthen Vaccine Development

Technology plays an important role in improving vaccine production, scalability, and responsiveness to emerging influenza strains. Egg-based technology accounted for 78.6% of the industry in 2021 and remains an established manufacturing approach because of its extensive commercial experience and existing production infrastructure.

At the same time, cell-based manufacturing is gaining attention as companies seek alternatives that can improve production flexibility and address certain limitations associated with traditional egg-based production. Investments in advanced manufacturing capabilities are expected to support the development of next-generation influenza vaccines.

By route of administration, injections represented the established delivery method, while the injection segment is projected to register a CAGR of 7.8% during 2022 to 2028. Nasal spray vaccines also provide an alternative administration route, particularly for populations where needle-free delivery may improve acceptance.

Government Initiatives and Strategic Investments Create Opportunities

Government support and investments by major vaccine manufacturers are strengthening production capacity and supply security. Sanofi announced an investment of approximately US$925 million in a new vaccine manufacturing facility in Toronto, Canada, designed to increase antigen and filling capacity for influenza vaccines. Similarly, Seqirus planned an investment of approximately US$800 million in a vaccine manufacturing center in Australia.

Government-backed procurement programs and long-term supply agreements are also supporting industry expansion. For example, GSK entered into an agreement with the Canadian government covering pandemic and seasonal influenza vaccines, including substantial potential supplies of pandemic vaccine and annual seasonal vaccine doses.

Key players operating in this space include:

• Sanofi
• GSK plc
• SEQIRUS
• Moderna, Inc.
• AstraZeneca plc
• Serum Institute of India Pvt. Ltd.
• Hualan Biological Engineering Inc.
• Emergent BioSolutions Inc.
• Mitsubishi Chemical Group Corporation
• Mylan N.V.

These companies are emphasizing product approvals, strategic collaborations, manufacturing expansion, and vaccine innovation to strengthen their competitive positions.

Regional Growth and Competitive Landscape

North America dominated the global industry with a 39.5% share in 2021, supported by established immunization programs, high healthcare expenditure, strong vaccine infrastructure, and favorable government initiatives. The US is projected to expand at a CAGR of 7.9% during the forecast period, supported by vaccination recommendations and increasing demand among high-risk populations.

Asia Pacific is expected to demonstrate significant growth, registering a projected CAGR of 7.9%. Rising healthcare investments, expanding vaccination awareness, improving healthcare infrastructure, and the growing focus on infectious disease prevention are supporting regional opportunities. Countries such as China, India, Japan, and Australia are increasingly important for manufacturers seeking geographic expansion.

Europe also represents a significant opportunity due to established vaccination programs and healthcare systems. Meanwhile, South and Central America and the Middle East and Africa offer long-term growth potential as governments expand immunization coverage and strengthen public health infrastructure.

Future Outlook

Growth will be shaped by rising influenza awareness, broader vaccination coverage, government procurement programs, manufacturing investments, and advances in vaccine technologies. Quadrivalent vaccines are expected to remain prominent, while cell-based production and innovative delivery approaches could create additional opportunities. Strategic partnerships, product approvals, and capacity expansion among leading manufacturers will remain important competitive strategies as healthcare systems prioritize preparedness against seasonal and pandemic influenza threats.

Related Report:

1) Pulp and Root Repair Market Size, Share, and Analysis by 2027

2) Medical Audiometer Devices Market Dynamics and Trends by 2028

3) Radiation Protection Apron Market Analysis, Size, and Share by 2030

About Us -

The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.

Contact Us:
Ankit Mathur | The Insight Partners
E-mail: [email protected]
Phone: +1-646-491-9876

Also Available in : Korean German Japanese French Chinese Italian Spanish